Clinical Case Employing Two Different Biomaterials in Bone Regeneration

The case of a 59-year-old woman lacking bone in the lower left side of her mandible, and treated with two different biomaterials for bone regeneration, is reported here. Specifically, two different anatomical sites damaged by two different pathologies were studied: a radicular fracture and peri-implantitis. The sites were treated via xenograft bone substitute and calcium phosphosilicate, respectively. Follow-up evaluations showed that the two different methodologies employing different materials in the same organism undergoing the same metabolic processes achieved the same good results. This represents a significant change in current surgical strategies for the dental region: instead of focusing on a single gold-standard technique, it is possible to follow a hybrid approach by adapting the biomaterial and the protocol used to the specificities of the defect.

CLINICAL COMPARISON OF 5% FLUORO CALCIUM PHOSPHOSILICATE VERSUS 5% CALCIUM SODIUM PHOSPHOSILICATE IN THE TREATMENT OF DENTINAL HYPERSENSITIVITY

Dentinal hypersensitivity is a perplexing problem for the patient as well as clinician. Among the plethora of pharmacological agents developed for the management of this rather common affliction, tubule occluding agents form the mainstay of treatment. Bioglasses (phosphosilicates) with evolving chemical and biological properties, are widely used, with the latest modification being the addition of fluoride to conventional calcium sodium phosphosilicate (Novamin) to result in fluoro calcium phosphosilicate (Biomin), purported to have superior tubule occlusive properties. The present study was designed as randomized clinical trial to compare the efficacy of Biomin and Novamin in reducing the subjective and provoked (thermal) experience of dentinal hypersensitivity. Sixty subjects were randomly prescribed three dentifrices after oral prophylaxis: Group A (20 patients): dentifrice containing 5% fluoro calcium phosphosilicate (Biomin); Group B (20 patients): dentifrice containing 5% calcium sodium phosphosilicate (Novamin); Group C (20 patients): standard dentifrice containing fluoride. Subjective and thermal sensitivity was assessed using a 10 point VAS score at baseline, at 15 days, 30 days and 60 days of treatment. It was found that though significant reduction in hypersensitivity was observed for all three groups over time, flouro calcium phosphosilicate was most effective in reducing the VAS score, followed by calcium sodium phosphosilicate and fluoride. It was concluded that fluoro calcium phosphosilicate is a promising agent for clinical management of dentinal hypersensitivity.

NovaboneTM dental putty as a potential regenerative material for treating horizontal defects in chronic periodontitis patients.

ntroduction: Periodontitis is a multifactorial disease, which, when not adequately treated, is followed with progressive attachment loss which leads to tooth mobility and eventually tooth loss. Periodontal regenerative surgery aims to regenerate and reconstruct the lost periodontal tissue. Regeneration with novabone putty has shown to be effective in reducing probing pocket depth, gain in clinical attachment level and increase in horizontal bone level. Aim: This interventional clinical trial was to evaluate the osseous regenerative potential of a calcium phosphosilicate bioactive glass NOVABONE TM in the treatment of horizontal bone defects. Materials and method: A total of 20 sites with horizontal bone defect was treated with open flap debridement with intra marrow penetration and novabone putty. Statistical analysis: Plaque index, gingival index and radiographic determination were analysed by paired t test. Probing pocket depth and clinical attachment levels were analysed by Wilcoxon Signed Ranks Test. Result: There was significant reduction seen in plaque index, gingival index, probing pocket depth and radiographic crestal level when compared between baseline and 12 months respectively (2.48 ± 0.44, 2.92 ± 0.39, 6.80 ± 0.89, 8.29 ± 0.87) and (1.89 ± 0.42, 1.92± 0.51, 3.00± 0.67, 5.48 ± 0.89) and significant gain in clinical attachment level from 4.40 ± 0.96 to 1.20 ± 0.91. Conclusion: The present study showed novabone putty significantly improved the clinical parameters in horizontal bone defects.